iShares Biotechnology ETF
IBB
894 hedge funds and large institutions have $5.28B invested in iShares Biotechnology ETF in 2024 Q2 according to their latest regulatory filings, with 78 funds opening new positions, 201 increasing their positions, 333 reducing their positions, and 65 closing their positions.
20% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 65
1.36% more ownership
Funds ownership: 69.54% → 70.9% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 11 → 11 (0)
1% less funds holding
Funds holding: 899 → 894 (-5)
1% less capital invested
Capital invested by funds: $5.32B → $5.28B (-$36.1M)
40% less repeat investments, than reductions
Existing positions increased: 201 | Existing positions reduced: 333
76% less call options, than puts
Call options by funds: $301M | Put options by funds: $1.27B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$117M |
| 2 |
Citigroup
New York
|
+$67M |
| 3 |
JP Morgan Chase
New York
|
+$53.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$29.1M |
| 5 |
Two Sigma Investments
New York
|
+$15.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$89M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$70.8M |
| 3 |
Millennium Management
New York
|
-$38.6M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$28.6M |
| 5 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$23.4M |
IBB Hedge Fund Activity: Q2 2024 in Review
894 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q2 2024, worth a combined $5.28B — down 0.68% from $5.32B a quarter earlier.
Buyers outnumbered sellers: 78 funds opened new IBB positions and 65 closed out — a net gain of 13 holders — while 201 added to existing stakes and 333 trimmed.
The largest buyer was Jane Street, adding an estimated $117M. The largest seller was Thrivent Financial for Lutherans, cutting an estimated $89M.
- 894 institutional investors held iShares Biotechnology ETF (IBB) as of Q2 2024, down from 899 in Q1 2024.
- Funds reported $5.28B of iShares Biotechnology ETF stock for Q2 2024, down 0.68% quarter-over-quarter.
- 78 funds opened new iShares Biotechnology ETF positions in Q2 2024 and 65 closed out, a net change of +13 holders.
- The largest iShares Biotechnology ETF buyer in Q2 2024 was Jane Street, an estimated $117M added.
- The largest iShares Biotechnology ETF seller in Q2 2024 was Thrivent Financial for Lutherans, an estimated $89M sold.
Based on aggregated 13F filings for Q2 2024.